home / stock / svra / svra short
Short Information | Savara Inc. (NASDAQ:SVRA)
Twenty Trading Day Totals | |
---|---|
Total Shorted Volume | 2,948,748 |
Total Actual Volume | 17,490,190 |
Short Trends | |
---|---|
Cover Days | 19 |
Short Days | 0 |
No Change Days | 1 |
Averages | |
---|---|
Average Short Volume | 147,437 |
Average Short Percentage | 16.14% |
Is there a SVRA Short Squeeze or Breakout about to happen?
See the SVRA Short Analysis for free Sign up or Login
Powered by Squeeze Report
Date | Open | Close | High | Low | Total Volume | Short Volume | Short Percentage |
---|---|---|---|---|---|---|---|
04-23-2024 | $4.68 | $4.69 | $4.78 | $4.63 | 479,493 | 65,395 | 13.64% |
04-22-2024 | $4.89 | $4.7 | $5.01 | $4.69 | 684,884 | 91,889 | 13.42% |
04-19-2024 | $4.75 | $4.81 | $4.825 | $4.6303 | 875,821 | 79,059 | 9.03% |
04-18-2024 | $4.95 | $4.79 | $5.005 | $4.79 | 1,204,829 | 254,846 | 21.15% |
04-17-2024 | $5.16 | $4.96 | $5.2 | $4.92 | 2,063,515 | 875,398 | 42.42% |
04-16-2024 | $5 | $5.16 | $5.3 | $4.9139 | 2,143,934 | 288,375 | 13.45% |
04-15-2024 | $5.01 | $5.04 | $5.145 | $4.885 | 1,857,117 | 134,855 | 7.26% |
04-12-2024 | $5.31 | $5.07 | $5.33 | $4.99 | 1,175,079 | 124,390 | 10.59% |
04-11-2024 | $4.77 | $5.34 | $5.34 | $4.77 | 1,675,682 | 169,834 | 10.14% |
04-10-2024 | $4.72 | $4.74 | $4.805 | $4.68 | 543,957 | 78,195 | 14.38% |
04-09-2024 | $4.74 | $4.9 | $4.925 | $4.64 | 380,809 | 74,017 | 19.44% |
04-08-2024 | $4.79 | $4.68 | $4.79 | $4.665 | 355,227 | 75,265 | 21.19% |
04-05-2024 | $4.59 | $4.78 | $4.82 | $4.5201 | 376,038 | 58,717 | 15.61% |
04-04-2024 | $4.81 | $4.61 | $4.85 | $4.59 | 378,293 | 51,863 | 13.71% |
04-03-2024 | $4.65 | $4.79 | $4.82 | $4.6 | 371,566 | 56,572 | 15.23% |
04-02-2024 | $4.8 | $4.67 | $4.8 | $4.62 | 383,626 | 57,228 | 14.92% |
04-01-2024 | $5 | $4.84 | $5 | $4.8 | 632,465 | 173,642 | 27.45% |
03-28-2024 | $4.88 | $4.98 | $4.995 | $4.845 | 904,349 | 106,860 | 11.82% |
03-27-2024 | $4.96 | $4.85 | $4.97 | $4.83 | 356,280 | 58,907 | 16.53% |
03-26-2024 | $4.87 | $4.91 | $4.93 | $4.83 | 647,226 | 73,441 | 11.35% |
News, Short Squeeze, Breakout and More Instantly...
Savara’s Partner, Trillium Health LLC, to Present Data on the Laboratory Blood Test for Diagnosing aPAP Company to Host Industry Theater on Pulmonary Alveolar Proteinosis (PAP) with Two World-Renowned Experts Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage ...
Remains On-Track to Report Top Line Data from the Pivotal Phase 3 IMPALA-2 Trial by End of 2Q 2024 48-week placebo-controlled trial is evaluating molgramostim nebulizer solution (molgramostim), a novel inhaled biologic, for the treatment of autoimmune Pulmonary Alveolar Proteinosis (aPAP)...
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will participate in a fireside chat at the Barclays 26th Annual Global Healthcare Conference on March 14, 2024 at 5:00am PT/8:00am ET. A live web...